Incyte Corporation

INCY

Biotech & pharmaceuticals

$127.58vs prev close▼-0.23(-0.18%)

$81.0952W Range$132.60

90% from low

+10.14 (+8.62%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.00%

1M -0.10%p

Holding ETFs

1 ETFs

ARKG

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -99.9% · Market value -99.9% · Weight -0.10%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.03.06	SELL	ARKG	93	$95.94	$8.9K
26.03.05	SELL	ARKG	1,084	$97.33	$105.5K
26.03.04	SELL	ARKG	27,013	$98.86	$2.7M
26.03.03	SELL	ARKG	101,963	$98.07	$10.0M
25.11.05	SELL	ARKG	13,092	$105.70	$1.4M
24.11.06	SELL	ARKG	24,347	$80.95	$2.0M
24.07.12	SELL	ARKG	21,517	$63.66	$1.4M
24.07.10	SELL	ARKG	62,152	$60.73	$3.8M
24.07.09	SELL	ARKG	51,641	$60.70	$3.1M
24.07.08	SELL	ARKG	27,886	$58.17	$1.6M
24.07.05	SELL	ARKG	9,070	$57.33	$520.0K
24.04.10	SELL	ARKG	3,647	$55.00	$200.6K
24.04.09	SELL	ARKG	9,973	$55.30	$551.5K
24.04.08	SELL	ARKG	14,462	$55.05	$796.1K
23.07.25	BUY	ARKG	90,653	$63.79	$5.8M

03.06SELL

ARKGClose$95.94Est. total$8.9K

03.05SELL

1,084

ARKGClose$97.33Est. total$105.5K

03.04SELL

27,013

ARKGClose$98.86Est. total$2.7M

03.03SELL

101,963

ARKGClose$98.07Est. total$10.0M

11.05SELL

13,092

ARKGClose$105.70Est. total$1.4M

11.06SELL

24,347

ARKGClose$80.95Est. total$2.0M

07.12SELL

21,517

ARKGClose$63.66Est. total$1.4M

07.10SELL

62,152

ARKGClose$60.73Est. total$3.8M

07.09SELL

51,641

ARKGClose$60.70Est. total$3.1M

07.08SELL

27,886

ARKGClose$58.17Est. total$1.6M

07.05SELL

9,070

ARKGClose$57.33Est. total$520.0K

04.10SELL

3,647

ARKGClose$55.00Est. total$200.6K

04.09SELL

9,973

ARKGClose$55.30Est. total$551.5K

04.08SELL

14,462

ARKGClose$55.05Est. total$796.1K

07.25BUY

90,653

ARKGClose$63.79Est. total$5.8M

1 / 2

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 1 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Ray DalioBridgewater Associates

Increased

328,590

Portfolio Weight

0.12%

Est. Value

$32M

vs Prev Quarter

+150% (131K→329K)

Sold · Q4 2025

Cathie WoodARK Invest

Fully Sold

Portfolio Weight

Prev Holdings

Est. Sold Value

$9K

Holding Period

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Sell

Analyst Targets

avg.

$125.17

vs Current ▼ -2.6% downside

Current$128.47

Low ~ High$86.00 ~ $155.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Piper Sandler

Overweight

$130.00

+1.19%

—

Maintain

2026-08-17

Mizuho

Outperform

$137.00

+6.64%

—

Maintain

2026-08-04

Leerink Partners

Outperform

$155.00

+20.65%

—

Maintain

2026-08-03

HC Wainwright & Co.

Buy

$150.00

+16.76%

—

Maintain

2026-08-03

RBC Capital

Sector Perform

$109.00

-15.16%

—

Maintain

2026-07-29

1 / 4

Avg Target

$125.17

vs Current ▼ -2.6% downside

Buy

27 analysts

Strong Buy 2Buy 9Hold 15Sell 1

Low $86.00

Current $128.47

High $155.00

Firm	Position	Target	Upside	Close	Action	Date
Piper Sandler	Overweight	$130.00	+1.19%	—	Maintain	26.08.17
Mizuho	Outperform	$137.00	+6.64%	—	Maintain	26.08.04
Leerink Partners	Outperform	$155.00	+20.65%	—	Maintain	26.08.03
HC Wainwright & Co.	Buy	$150.00	+16.76%	—	Maintain	26.08.03
RBC Capital	Sector Perform	$109.00	-15.16%	—	Maintain	26.07.29

1 / 4

Price Information

Previous Close$127.81

Open$126.74

Day Range$126.52 - $129.92

52-Week Range$81.09 - $132.60

1-Year Change50.79%

Trading Volume

Volume1,367,411

Avg Volume (3mo)1,895,669

Valuation

Market Cap25.9B

Book Value$31.57

Shares Outstanding202,697,746

Financials

Revenue (TTM)5.8B

Net Income1.6B

EPS$7.85

EBITDA1.9B

Profitability

P/E Ratio16.28

P/B Ratio4.05

Return on Equity (ROE)30.67%

Return on Assets (ROA)16.83%

Profit Margin27.71%

EV/EBITDA11.02

Beta0.77

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)74.48

Company Overview

Incyte Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for various cancers and inflammatory diseases. Their main products include treatments for myelofibrosis, lymphoma, biliary tract cancer, and graft-versus-host disease, with a pipeline of additional drugs in clinical development. Incyte operates globally, selling its products through various pharmacy and distribution channels.

P/B

4.05

High valuation

ROE

30.7%

High return

Beta

0.77

Market level

RSI(14)

74.5

Overbought

AI-generated summary. Not investment advice.

Incyte Corporation

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks